MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
Moderna DSO Ratio 2011-2026 | MRNA
Annual DSO Ratio Moderna
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.9 | 70.5 | 60.7 | 43.2 | 45.1 | 317 | 98.8 | 82.6 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 317 | 43.2 | 96.1 |
Quarterly DSO Ratio Moderna
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.6 | 36.6 | 184 | - | 42.3 | 56.8 | 281 | - | 52.3 | 178 | 61.2 | - | 36.5 | 30.5 | 47.8 | - | 47.4 | 54.8 | 108 | - | 808 | 1.89 K | 7.96 K | 34.9 | 28.7 | 36.3 | 47.6 | 30.1 | 25.5 | 37 | 37 | 5.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.96 K | 5.9 | 452 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M |  USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 4.57 | -0.22 % | $ 11 B |  Australia |
 |
Compugen Ltd.
CGEN
|
60.8 | $ 2.65 | -2.93 % | $ 248 M |  Israel |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.88 | - | $ 6.47 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.5 | -0.75 % | $ 3.73 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Galapagos NV
GLPG
|
56.5 | $ 27.55 | -3.08 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
97.9 | $ 25.89 | -3.36 % | $ 16 B |  Danmark |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | USA |
 |
Innoviva
INVA
|
24.6 | $ 23.23 | -1.94 % | $ 1.57 B | USA |
 |
Aquestive Therapeutics
AQST
|
103 | $ 4.07 | -0.61 % | $ 435 M | USA |
 |
Jaguar Health
JAGX
|
48.3 | $ 0.23 | -5.27 % | $ 536 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 22.56 | -3.13 % | $ 2.87 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
9.64 | $ 26.71 | 38.8 % | $ 1.44 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.4 | -5.74 % | $ 373 M | Britain |
 |
Kamada Ltd.
KMDA
|
103 | $ 8.15 | - | $ 260 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 2.88 | -1.03 % | $ 4.74 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |